期刊文献+

恶性萎缩性丘疹病的研究进展 被引量:5

Malignant atrophic papulosis
原文传递
导出
摘要 恶性萎缩性丘疹病是一种以萎缩性丘疹样皮损为特征的疾病,常伴有多系统脏器受累,死因多为胃肠穿孔和频发弥漫性腹膜炎。恶性萎缩性丘疹病发病原因尚不明,可能与免疫功能紊乱、高凝状态、纤维溶解蛋白异常、基因易感性、病毒和细菌感染有关。组织病理:血管腔纤维性增生和纤维蛋白血栓形成引起血管阻塞。免疫组化检查提示,膜攻击复合物、基质细胞衍生因子1/趋化因子12等因子有不同程度的沉积。恶性萎缩性丘疹病至今尚无有效的治疗方法,需要进一步研究。 Malignant atrophic papulosis is a rare disease characterized by atrophic papular skin lesions, and usually affects multiple systems and organs. Patients with malignant atrophic papulosis usually die from gastrointestinal perforation or frequent diffuse peritonitis. The exact pathogenesis of this disease is still unclear, and may be associated with immunological dysfunction, hypercoagulation, aberrant fibrinolysis, gene susceptibility, viral and bacterial infections. Histopathologically, it is characterized by vascular occlusion caused by fibrous hyperplasia and fibrinous thrombosis formation in lumina of blood vessels. As immunohistochemical staining shows, there are different degrees of deposites of C5b-9 and SDF-1/CXCL12. No effective treatment has been available for Degos disease up to now, and further researches are still needed.
出处 《国际皮肤性病学杂志》 2016年第5期413-416,共4页 International Journal of Dermatology and Venereology
关键词 恶性萎缩性丘疹病 遗传 基因 突变 病理学 治疗结果 Malignant atrophic papulosis Heredity Genes Mutation Pathology Treatment outcome
  • 引文网络
  • 相关文献

参考文献23

  • 1Theodoridis A, Konstantinidou A, Makrantonaki E, et al. Malignant and benign forms of atrophic papulosis (Kfihlmeier- Degos disease): systemic involvement determines the prognosis [J]. Br J Dermatol, 2014, 170 (1): 110-115. DOI :10.1111/bjd. 12642.
  • 2Lima Lde A, Haddad Nde C, Lima RB, et al. Case for diagnosis [J]. An Bras Dermatol, 2014, 89(3): 521-522.
  • 3Hohwy T, Jensen MG, Tcttrup A, et al. A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant [J]. Acta Derm Venereol, 2006, 86(3): 245-247, DOI: 10.2340/00015555-0068.
  • 4Torrelo A, Sevilla J, Mediero IG, et al. Malignant atrophic papulosis in an infant [J]. Br J Dermatol, 2002, 146 (5): 916- 918.
  • 5Umemura M, Miwa Y, Yanai R, et al. A case of Degos disease: demonstration of C5b-9-mediated vascular injury [J]. Mod Rheumatol, 2015, 25 (3): 480-483. DOI: 10.3109/14397595. 2013.874761.
  • 6Magro CM, Wang X, Garrett-Bakelman F, et ak The effects ofeculizumab on the pathology of malignant atrophm papulosls LJ J. Orphanet J Rare Dis, 2013, 8: 185. DOI: 10.1186/1750-1172-8- 185.
  • 7Meephansan J, Komine M, Hosoda S, et al. Possible involvement of SDF-1/CXCLI2 in the pathogenesis of Degos disease [J]. J Am Aead Dermatol, 2013, 68 (1): 138-143. DOI: 10.1016/j.jaad.2012.06.031.
  • 8Pirolla E, Fregni F, Miura IK, et al. Degos disease - malignant atrophic papulosis or eutaneointestinal lethal syndrome: rarity of the disease [J]. Clin Exp Gastroenterol, 2015, 8: 141-147. DOI: 10.2147/CEG.$59794.
  • 9Toledo AE, Shapiro LS, Farrell JF, et al. Laparoscopy shows superiority over endoscopy for early detection of malignant atrophic papulosis gastrointestinal complications: a case report and review of literature [J]. BMC Gastroenterol, 2015, 15: 156. DOI: 10.1186/sl 2876-015-0387-y.
  • 10Karaoglu P, Top~u Y, Bayram E, et al. Severe neurologie involvement of Degos disease in a pediatric patient [J]. J Child Neurol, 2014, 29(4): 550-554. DOI: 10.1177/0883073812474692.

同被引文献13

引证文献5

二级引证文献4

;
使用帮助 返回顶部